Cancer drug under watch: Real-World safety study launches in korea
NCT ID NCT04982848
Summary
This study will monitor the real-world safety and effectiveness of Talzenna, a drug already approved for treating advanced breast cancer with specific genetic mutations (gBRCA) in Korea. It will observe 600 patients who are prescribed Talzenna by their doctors as part of normal medical care. The goal is to collect information on side effects and how well the drug works outside of controlled clinical trials.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST NEOPLASMS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.